var data={"title":"Lorazepam: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Lorazepam: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6480?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=lorazepam-patient-drug-information\" class=\"drug drug_patient\">see &quot;Lorazepam: Patient drug information&quot;</a> and <a href=\"topic.htm?path=lorazepam-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Lorazepam: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49334833\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Risks from concomitant use with opioids:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189926\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Ativan;</li>\n      <li>LORazepam Intensol</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50781432\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Ativan</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189973\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Anticonvulsant, Benzodiazepine;</li>\n      <li>\n        Benzodiazepine</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189931\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anxiety disorder:</b> Oral: Initial: 2 to 3 mg daily in 2 to 3 divided doses; usual dose: 2 to 6 mg daily in divided doses; however, daily dose may vary from 1 to 10 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Insomnia due to anxiety or stress:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&lt;65 years: 0.5 to 2 mg at bedtime (Winkelman 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&ge;65 years: 0.5 to 1 mg at bedtime (Winkelman 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> The manufacturer recommends higher dosing (ie, 2 to 4 mg at bedtime); however, generally, it is a safer approach to employ the above recommended doses.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Premedication for anesthesia:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM: 0.05 mg/kg administered 2 hours before surgery (maximum dose: 4 mg)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 0.044 mg/kg administered 15 to 20 minutes before surgery (usual dose: 2 mg; maximum dose: 4 mg). <b>Note:</b> Doses &gt;2 mg should generally not be exceeded in patients &gt;50 years.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Sublingual tablet [Canadian product]: 0.05 mg/kg 1 to 2 hours before surgery (maximum dose: 4 mg)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Status epilepticus:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>American Epilepsy Society and Neurocritical Care Society recommendations:</i> 0.1 mg/kg (maximum dose: 4 mg) given at a maximum rate of 2 mg/minute; may repeat in 5 to 10 minutes (AES [Glauser 2016]; NCS [Brophy 2012]). <b>Note:</b> Dilute dose 1:1 with saline.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Manufacturer's labeling:</i> 4 mg given slowly (2 mg/minute); may repeat in 10 to 15 minutes. May be given IM, but IV preferred.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Agitation in the ICU patient (off-label use):</b> IV: Loading dose: 0.02 to 0.04 mg/kg (maximum single dose: 2 mg); Maintenance: 0.02 to 0.06 mg/kg every 2 to 6 hours as needed <b>or</b> 0.01 to 0.1 mg/kg/hour; maximum dose: &le;10 mg/hour (Barr 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Alcohol withdrawal delirium (off-label use) (Mayo-Smith 2004):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 1 to 4 mg every 5 to 15 minutes until calm, then every hour as needed to maintain light somnolence</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM: 1 to 4 mg every 30 to 60 minutes until calm, then every hour as needed to maintain light somnolence</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Alcohol withdrawal syndrome (off-label use): </b>\n      <b>Note: </b>Symptom-triggered regimens preferred over fixed-dose regimens; lower doses and shorter durations of treatment are needed (Soyka 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Symptom-triggered regimen: Oral, IM, IV: 2 to 4 mg every 1 hour as needed; dose determined by a validated severity assessment scale (Mayo-Smith 1997)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Fixed-dose regimen: Oral, IM, IV: 2 mg every 6 hours for 4 doses, then 1 mg every 6 hours for 8 additional doses (Mayo-Smith 1997)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chemotherapy-associated nausea and vomiting (off-label use): </b> Breakthrough nausea/vomiting or as adjunct to standard antiemetics: Oral, IV, Sublingual (off-label route): 0.5 to 2 mg every 6 hours as needed (Lohr 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Psychogenic catatonia (off-label use):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM, Sublingual (off-label route): 1 to 2 mg; repeat dose in 3 hours then again in another 3 hours if initial and subsequent doses, respectively, are ineffective (Rosebush 1990, Rosebush 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral, IM, IV: Initial: 1 mg; may repeat in 5 minutes if necessary. If initial challenge is unsuccessful, may increase dose up to 4 to 8 mg per day; may continue treatment for up to 5 days (Bush 1996).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Rapid tranquilization of the agitated patient (off-label use):</b> Oral, IM, IV: 1 to 3 mg administered every 30 to 60 minutes; may be administered with an antipsychotic (eg, haloperidol) (Allen 2005; Battaglia 2005; De Fruyt 2004; Wilson 2012). <b>Note:</b> When administering IM, may consider a lower initial dose (eg, 0.5 mg) (Allen 2005).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosage adjustment for lorazepam with concomitant medications:</b> <i>Probenecid or valproic acid:</i> Reduce lorazepam dose by 50%</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189951\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=lorazepam-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Lorazepam: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chemotherapy-associated nausea and vomiting (off-label use): </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Anticipatory nausea/vomiting (prevention and treatment):</i> Infants &ge;1 month, Children, and Adolescents: Oral: 0.04 to 0.08 mg/kg/dose (maximum dose: 2 mg) once at bedtime the evening prior to chemotherapy and once the next day before chemotherapy (Dupuis 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i> Breakthrough nausea/vomiting:</i> Children &ge;2 years and Adolescents: IV: 0.025 to 0.05 mg/kg/dose (maximum dose: 2 mg) every 6 hours as needed (Dupuis 2003).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Status epilepticus:</b> Infants, Children, and Adolescents (off-label use):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>American Epilepsy Society and Neurocritical Care Society recommendations:</i> IV: 0.1 mg/kg (maximum dose: 4 mg) given at a maximum rate of 2 mg/minute; may repeat in 5 to 10 minutes (AES [Glauser 2016]; NCS [Brophy 2012]). <b>Note:</b> Dilute dose 1:1 with saline.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>American Academy of Pediatrics recommendation:</i> IV, IM: 0.05 to 0.1 mg/kg (maximum dose: 4 mg); may repeat dose every 10 to 15 minutes if seizure continues (AAP [Hegenbarth 2008])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosage adjustment for lorazepam with concomitant medications:</b> <i>Probenecid or valproic acid:</i> Reduce lorazepam dose by 50%</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189932\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer also to adult dosing. Dose selection should generally be on the low end of the dosage range (initial dose not to exceed 2 mg).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anxiety disorder:</b> Oral: Initial: 1 to 2 mg daily in divided doses</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4413000\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: No dosage adjustment necessary (Aronoff 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild-to-moderate impairment: No dosage adjustment necessary for acute doses; use repeated doses with caution; may increase the risk of propylene glycol toxicity. Monitor closely if using for prolonged periods of time or at high doses.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe impairment or failure: Use is not recommended.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4413001\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild-to-moderate impairment: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe impairment and/or encephalopathy: Use with caution; may require lower doses.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild-to-moderate impairment: No dosage adjustment necessary; use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe impairment or failure: Use is not recommended.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189896\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Concentrate, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">LORazepam Intensol: 2 mg/mL (30 mL) [alcohol free, dye free, sugar free; unflavored flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2 mg/mL (30 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ativan: 2 mg/mL (1 mL, 10 mL); 4 mg/mL (1 mL, 10 mL) [contains benzyl alcohol, polyethylene glycol, propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2 mg/mL (1 mL, 10 mL); 4 mg/mL (1 mL, 10 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg/100 mL (100 mL); 100 mg/100 mL in NaCl 0.9% (100 mL); 60 mg/60 mL in NaCl 0.9% (60 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ativan: 0.5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ativan: 1 mg, 2 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.5 mg, 1 mg, 2 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189880\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24129223\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, Sublingual: 0.5 mg, 1 mg, 2 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189975\" class=\"block csi drugH1Div\"><span class=\"drugH1\">Controlled Substance</span>\n    <p style=\"text-indent:0em;display:inline\">C-IV</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49468920\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Ativan: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/017794s044lbl.pdf&amp;token=Iam5bqtuLpuhJgT3VdiHUYlWaj8qFV36o/IJZx8ZKogdmhCKhS+2IqAAzAIpNLUin4XXyyRCUE4NcTDbFZ5I94kdHs1ykIu5iATe6SXgcZw=&amp;TOPIC_ID=9573\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/017794s044lbl.pdf</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189901\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IM: Should be administered (undiluted) deep into the muscle mass.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IV injection: Dilute prior to use (according to the manufacturer). Do not exceed 2 mg/minute or 0.05 mg/kg over 2 to 5 minutes. Monitor IV site during administration. Avoid intra-arterial administration. Avoid extravasation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Continuous IV infusion (off-label administration mode; Barr 2013) solutions should have an in-line filter and the solution should be checked frequently for possible precipitation (Grillo 1996).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral: Lorazepam oral concentrate: Use only the provided calibrated dropper to withdraw the prescribed dose. Mix the dose with liquid (eg, water, juice, soda, soda-like beverage) or semisolid food (eg, applesauce, pudding), and stir for a few seconds to blend completely. The prepared mixture should be administered immediately. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sublingual tablet [Canadian product]: Place under tongue; patient should not swallow for at least 2 minutes.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189900\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anxiety (oral):</b> Management of anxiety disorders, short-term (&le;4 months) relief of anxiety symptoms, or anxiety associated with depressive symptoms, or anxiety/stress-associated insomnia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anesthesia premedication (parenteral):</b> Anesthesia premedication in adults to relieve anxiety or to produce amnesia (diminish recall) or sedation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anesthesia premedication (sublingual) [Canadian product]: </b> Anesthesia premedication to relieve anxiety prior to surgical procedures.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Status epilepticus (parenteral):</b> Treatment of status epilepticus.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25472939\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Agitation in the ICU patient; Alcohol withdrawal delirium; Alcohol withdrawal syndrome; Chemotherapy-associated nausea and vomiting (adjunct or breakthrough) (adults); Chemotherapy-associated nausea and vomiting (adjunct or breakthrough) (children/adolescents); Chemotherapy-associated nausea and vomiting (anticipatory) (children/adolescents); Psychogenic catatonia; Rapid tranquilization of the agitated patient; Status epilepticus (infants, children, and adolescents)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189983\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">LORazepam may be confused with ALPRAZolam, clonazePAM, diazePAM, KlonoPIN, Lovaza, temazepam, zolpidem</p>\n        <p style=\"text-indent:0em;margin-left:2em;\">Ativan may be confused with Ambien, Atarax, Atgam, Avitene</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Lorazepam is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (independent of diagnosis or condition) because of increased risk of impaired cognition, delirium, falls, fractures, and motor vehicle accidents with benzodiazepine use (Beers Criteria [AGS 2015]).</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Injection dosage form contains propylene glycol. Monitor for toxicity when administering continuous or high-dose lorazepam infusions.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189887\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Frequency not always defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Hypotension (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Sedation (&le;16%), dizziness (&le;7%), drowsiness (2% to 4%), unsteadiness (3%), headache (1%), coma (&le;1%), stupor (&le;1%), aggressive behavior, agitation, akathisia, amnesia, anxiety, central nervous system stimulation, disinhibition, disorientation, dysarthria, euphoria, excitement, extrapyramidal reaction, fatigue, hostility, hypothermia, irritability, mania, memory impairment, outbursts of anger, psychosis, seizures, sleep apnea (exacerbation), sleep disturbances, slurred speech, suicidal behavior, suicidal ideation, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Alopecia, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Changes in appetite, constipation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Change in libido, hyponatremia, SIADH</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Impotence, orgasm disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Agranulocytosis, pancytopenia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Increased serum alkaline phosphatase, increased serum bilirubin, increased serum transaminases, jaundice</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hypersensitivity: Anaphylaxis, anaphylactoid reaction, hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Local: Pain at injection site (IM: 1% to 17%; IV: &le;2%), erythema at injection site (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Weakness (&le;4%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ophthalmic: Visual disturbances (including diplopia and blurred vision)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Respiratory failure (1% to 2%), apnea (1%), hypoventilation (&le;1%), exacerbation of obstructive pulmonary disease, nasal congestion, respiratory depression, worsening of sleep apnea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports: Abnormal gait, abnormal hepatic function tests, abnormality in thinking, acidosis, cardiac arrhythmia, ataxia, blood coagulation disorder, bradycardia, cardiac arrest, cardiac failure, cerebral edema, chills, confusion, convulsions, cystitis, decreased mental acuity, delirium, depression, drug dependence (with prolonged use), drug toxicity (polyethylene glycol or propylene glycol poisoning [prolonged IV infusion]), excessive crying, gastrointestinal hemorrhage, hallucinations, hearing loss, heart block, hematologic abnormality, hepatotoxicity, hypertension, hyperventilation, hyporeflexia, infection, injection site reaction, myoclonus, nausea, nervousness, neuroleptic malignant syndrome, paralysis, pericardial effusion, pheochromocytoma (aggravation), pneumothorax, pulmonary edema, pulmonary hemorrhage, pulmonary hypertension, restlessness, seizure, sialorrhea, tachycardia, tremor, urinary incontinence, ventricular arrhythmia, vomiting, withdrawal syndrome</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189904\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to lorazepam, any component of the formulation, or other benzodiazepines (cross-sensitivity with other benzodiazepines may exist); acute narrow-angle glaucoma; severe respiratory insufficiency (except during mechanical ventilation)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Additional contraindications: Hypersensitivity to polyethylene glycol, propylene glycol, or benzyl alcohol; sleep apnea; intra-arterial injection; use in premature infants</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Myasthenia gravis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189884\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anterograde amnesia: Benzodiazepines have been associated with anterograde amnesia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Paradoxical reactions: Paradoxical reactions, including hyperactive or aggressive behavior, have been reported with benzodiazepines, particularly in adolescent/pediatric or psychiatric patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug abuse: Risk of dependence increases in patients with a history of alcohol or drug abuse and those with significant personality disorders; use with caution in these patients. Tolerance, psychological and physical dependence may also occur with higher dosages and prolonged use. The risk of dependence is decreased with short-term treatment (2 to 4 weeks); evaluate the need for continued treatment prior to extending therapy duration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment, insufficiency, and/or encephalopathy. Dose adjustment (lower doses) may be needed. May worsen hepatic encephalopathy. Parenteral use is not recommended in patients with hepatic failure.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Impaired gag reflex: Use with caution in patients with an impaired gag reflex.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Psychiatric disorders: Preexisting depression may emerge or worsen during therapy. Not recommended for use in primary depressive or psychotic disorders. Should not be used in patients at risk for suicide without adequate antidepressant treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment. Parenteral use is not recommended in patients with renal failure.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory disease: Use with caution in patients with respiratory disease, including COPD or sleep apnea. Benzodiazepines may cause significant respiratory depression.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Concomitant use with opioids: <b>[US Boxed Warning]: </b><b>Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for use in patients for whom alternative </b><b>treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation.</b> In patients already receiving an opioid analgesic, prescribe a lower initial dose of lorazepam than indicated in the absence of an opioid and titrate based on clinical response. If an opioid is initiated in a patient already taking lorazepam, prescribe a lower initial dose of the opioid and titrate based upon clinical response.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Debilitated patients: Use with caution in debilitated patients; initial doses should be at the lower end of dosing range.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fall risk: Use with extreme caution in patients who are at risk of falls; benzodiazepines have been associated with falls and traumatic injury.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatrics: In pediatric and neonatal patients &lt;3 years, the repeated or lengthy exposure to sedatives or anesthetics during surgery/procedures may have detrimental effects on the child's brain development and may contribute to various cognitive and behavioral problems. Epidemiological studies have reported various cognitive and behavioral problems including neurodevelopmental delay (and related diagnoses), learning disabilities, and ADHD. Clinical data suggest that single, relatively short exposures are not likely to have similar negative effects. Further studies are needed to fully characterize findings and ensure that these findings are not related to underlying conditions or the procedure itself. No specific anesthetic/sedative has been found to be safer. For elective procedures, risk vs benefits should be evaluated and discussed with parents/caregivers/patients; critical surgeries should not be delayed (<a target=\"_blank\" href=\"https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm555631.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery&amp;token=YLy9c1sPZ/dHcqpzSuYgJdvuqUyvZWbMw+T4Q+fsbqW4JQlh3SbPN+UEnwg89nd5uWp4cid3WcHgE8E+YPsnho7ksvMXf2W/1bGGHC2/bOlcHBJNlxiua1RLIuBi4LS6hH0eJn6CRGL08achIDEibpee07SPOtQh1cHI+27+lhQ4jr1lNuZ0oUZfKxD9OHFT&amp;TOPIC_ID=9573\" target=\"_blank\">FDA 2016</a>).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polyethylene glycol: Parenteral formulation may contain polyethylene glycol. May be associated with toxicity in high-dose and/or longer-term therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Propylene glycol: Parenteral formulation may contain propylene glycol; large amounts are potentially toxic and have been associated with hyperosmolality, lactic acidosis, seizures and respiratory depression; use caution (AAP 1997; Zar 2007). See manufacturer's labeling. May consider using enteral delivery of lorazepam tablets to decrease the risk of propylene glycol toxicity (Lugo 1999).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Does not have analgesic, antidepressant, or antipsychotic properties. Status epilepticus should not be treated with injectable benzodiazepines alone; requires close observation and management and possibly ventilatory support. When used as a component of preanesthesia, monitor for heavy sedation and airway obstruction; equipment necessary to maintain airway and ventilatory support should be available.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypnotic: Appropriate use: As a hypnotic, should be used only after evaluation of potential causes of sleep disturbance. Failure of sleep disturbance to resolve after 7 to 10 days may indicate psychiatric or medical illness. A worsening of insomnia or the emergence of new abnormalities of thought or behavior may represent unrecognized psychiatric or medical illness and requires immediate and careful evaluation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tolerance: Lorazepam is a short half-life benzodiazepine. Duration of action after a single dose is determined by redistribution rather than metabolism. Tolerance develops to the sedative, hypnotic, and anticonvulsant effects. It does not develop to the anxiolytic effects (Vinkers 2012). Chronic use of this agent may increase the perioperative benzodiazepine dose needed to achieve desired effect.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Withdrawal: Rebound or withdrawal symptoms may occur following abrupt discontinuation or large decreases in dose. Use caution when reducing dose or withdrawing therapy; decrease slowly and monitor for withdrawal symptoms. Flumazenil may cause acute withdrawal in patients receiving long-term benzodiazepine therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299616\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189889\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9573&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benznidazole: May enhance the adverse/toxic effect of Products Containing Propylene Glycol.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine patches (Butrans brand) at 5 mcg/hr in adults when used with other CNS depressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Benzodiazepines may enhance the adverse/toxic effect of CloZAPine.  Management: Consider decreasing the dose of (or possibly discontinuing) benzodiazepines prior to initiating clozapine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxylamine: May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is  not recommended.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: Benzodiazepines may increase the serum concentration of Fosphenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CNS Depressants may enhance the CNS depressant effect of HYDROcodone.  Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kava Kava: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loxapine: May enhance the adverse/toxic effect of LORazepam. Specifically, prolonged stupor, respiratory depression, and/or hypotension.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Melatonin: May enhance the sedative effect of Benzodiazepines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methadone: Benzodiazepines may enhance the CNS depressant effect of Methadone.  Management: Clinicians should generally avoid concurrent use of methadone and benzodiazepines when possible; any combined use should be undertaken with extra caution.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OLANZapine: May enhance the adverse/toxic effect of Benzodiazepines. Management: Avoid concomitant use of parenteral benzodiazepines and IM olanzapine due to risks of additive adverse events (e.g., cardiorespiratory depression). Olanzapine prescribing information provides no specific recommendations regarding oral administration.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: CNS Depressants may enhance the CNS depressant effect of Opioid Analgesics.  Management: Avoid concomitant use of opioid analgesics and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: Benzodiazepines may increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of LORazepam.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Oxybate: Benzodiazepines may enhance the CNS depressant effect of Sodium Oxybate. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol: May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teduglutide: May increase the serum concentration of Benzodiazepines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Theophylline Derivatives: May diminish the therapeutic effect of Benzodiazepines.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Valproate Products: May increase the serum concentration of LORazepam.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Yohimbine: May diminish the therapeutic effect of Antianxiety Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189908\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Lorazepam and its metabolite cross the human placenta. Teratogenic effects in humans have been observed with some benzodiazepines (including lorazepam); however, additional studies are needed. The incidence of premature birth and low birth weights may be increased following maternal use of benzodiazepines; hypoglycemia and respiratory problems in the neonate may occur following exposure late in pregnancy. Neonatal withdrawal symptoms may occur within days to weeks after birth and &ldquo;floppy infant syndrome&rdquo; (which also includes withdrawal symptoms) have been reported with some benzodiazepines (including lorazepam). Elimination of lorazepam in the newborn infant is slow; following in utero exposure, term infants may excrete lorazepam for up to 8 days (Bergman 1992; Iqbal 2002; Wikner 2007).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189909\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lorazepam is present in breast milk.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">The relative infant dose (RID) of lorazepam is 2.4% to 4.7% when calculated using the highest breast milk concentration located following benzodiazepine monotherapy with lorazepam and compared to an infant therapeutic dose of 0.15 to 0.3 mg/kg/day (0.05 mg/kg/dose every 4 to 8 hours). In general, breastfeeding is considered acceptable when the RID is &lt;10% (Anderson 2016; Ito 2000); however, some sources note breastfeeding should only be considered if the RID is &lt;5% for psychotropic agents (Larsen 2015). Using the highest total milk concentration (12 mcg/L free lorazepam plus 35 mcg/L conjugated lorazepam), the estimated the daily infant dose via breast milk is 7.05 mcg/kg/day. These milk concentrations were obtained following maternal administration of oral lorazepam 2.5 mg twice daily for the first five days postpartum; the mother had begun treatment with lorazepam prior to delivery (route, dose, and duration not specified) (Whitelaw 1981). Higher milk concentrations were observed in one mother who received both oral lorazepam and lormetazepam, which is partially metabolized to lorazepam (Lemmer 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">In general, sedation, lethargy, irritability, poor weight gain, and apnea have been reported in breastfed infants exposed to benzodiazepines; however, these adverse effects were not observed in breastfed infants exposed to lorazepam (Kelly 2012). The manufacturer warns of the potential for sedation, irritability, and impaired suckling in the infant. Monitor breastfed infants for drowsiness (WHO 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Although the manufacturer recommends that lorazepam should not be administered to breastfeeding women unless the expected benefit to the woman outweighs the potential risk to the infant, short-acting benzodiazepines, including lorazepam, are considered compatible with breastfeeding (WHO 2002; Kelly 2012). When possible, limit exposure to single doses (WHO 2002).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189893\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Respiratory and cardiovascular status, blood pressure, heart rate, symptoms of anxiety</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Long-term therapy: CBC, liver function tests, LDH</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">High-dose or continuous IV use or IV use in patients with renal impairment: Clinical signs of propylene glycol toxicity, serum creatinine, BUN, serum lactate, osmolal gap; <b>Note:</b> An osmolal gap of &ge;10 was predictive of elevated propylene glycol concentrations; values of &ge;12 suggest propylene glycol toxicity (Barnes 2006; Yahwak 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Critically-ill patients: Monitor depth of sedation with either the Richmond Agitation-Sedation Scale (RASS) or Sedation-Agitation Scale (SAS) (Barr 2013)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189883\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Binds to stereospecific benzodiazepine receptors on the postsynaptic GABA neuron at several sites within the central nervous system, including the limbic system, reticular formation. Enhancement of the inhibitory effect of GABA on neuronal excitability results by increased neuronal membrane permeability to chloride ions. This shift in chloride ions results in hyperpolarization (a less excitable state) and stabilization. Benzodiazepine receptors and effects appear to be linked to the GABA-A receptors. Benzodiazepines do not bind to GABA-B receptors.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189903\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Anticonvulsant: IV: Within 10 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypnosis: IM: 20 to 30 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Sedation: IV: Within 2 to 3 minutes (Greenblatt 1983)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: Anesthesia premedication: Adults: IM, IV: ~6 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: IM: Rapid and complete absorption; Oral: Readily absorbed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: IV: V<sub>d</sub>:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neonates: 0.76 &plusmn; 0.37 L/kg (range: 0.14 to 1.3 L/kg) (McDermott 1992)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pediatric patients (Chamberlain 2012):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">5 months to &lt; 3 years: 1.62 L/kg (range: 0.67 to 3.4 L/kg)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">3 to &lt;13 years: 1.5 L/kg (range: 0.49 to 3 L/kg)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">13 to &lt;18 years: 1.27 L/kg (range: 1 to 1.54 L/kg)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 1.3 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~91%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic; rapidly conjugated to lorazepam glucuronide (inactive)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Oral: 90%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Full-term neonates: IV: 40.2 &plusmn; 16.5 hours; range: 18 to 73 hours (McDermott 1992)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pediatric patients (Chamberlain 2012): IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">5 months to &lt;3 years: 15.8 hours (range: 5.9 to 28.4 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">3 to &lt;13 years: 16.9 hours (range: 7.5 to 40.6 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">13 to &lt;18 years: 17.8 hours (range: 8.2 to 42 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: Oral: ~12 hours; IV: ~14 hours; IM: ~13 to 18 hours (Greenblatt 1983); End-stage renal disease (ESRD): ~18 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: IM: &le;3 hours; Oral: ~2 hours; Sublingual tablet [Canadian product]: 1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (~88%; predominantly as inactive metabolites); feces (~7%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189907\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Concentrate</b> (LORazepam Intensol Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg/mL (30 mL): $48.03</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Concentrate</b> (LORazepam Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg/mL (30 mL): $48.03</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Ativan Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg/mL (1 mL): $2.08</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg/mL (1 mL): $2.88</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (LORazepam Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg/mL (1 mL): $2.02</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg/mL (1 mL): $2.05</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (LORazepam-Dextrose Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/100 mL 5% (100 mL): $50.15</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (LORazepam-Sodium Chloride Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/100 mL 0.9% (100 mL): $49.64</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Ativan Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg (100): $2,798.04</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (100): $3,737.77</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (100): $5,956.84</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (LORazepam Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg (100): $64.31</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (100): $83.77</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (100): $127.36</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189910\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Abinol (CL);</li>\n      <li>Ansilor (PT);</li>\n      <li>Anta (TH);</li>\n      <li>Anxiar (RO);</li>\n      <li>Anxira (TH);</li>\n      <li>Anzepam (TW);</li>\n      <li>Aplacasse (AR);</li>\n      <li>Aripax (GR);</li>\n      <li>Ativan (AE, AU, BB, BF, BH, BJ, CI, CO, EG, ET, GB, GH, GM, GN, IE, IN, JO, KE, KR, KW, LR, MA, ML, MR, MT, MU, MW, MX, NE, NG, NZ, PE, PH, PK, QA, SA, SC, SD, SG, SL, SN, TN, TW, TZ, UG, UY, VE, VN, ZA, ZM, ZW);</li>\n      <li>Bonatranquan (DE);</li>\n      <li>Control (IT);</li>\n      <li>Donix (ES);</li>\n      <li>Emotival (AR);</li>\n      <li>Larpose (IN, LK);</li>\n      <li>Laubeel (DE);</li>\n      <li>Lauracalm (LU);</li>\n      <li>Lonza (TH);</li>\n      <li>Lopa (BD);</li>\n      <li>Lopam (TW);</li>\n      <li>Lora (CN);</li>\n      <li>Lorabenz (DK);</li>\n      <li>Lorafen (LV, PL);</li>\n      <li>Loram (HR);</li>\n      <li>Lorans (AE, BH, CY, EG, IQ, IR, IT, JO, KW, LB, LT, LY, MT, MY, OM, QA, SA, SY, YE);</li>\n      <li>Loranxil (HU);</li>\n      <li>Loravan (KR);</li>\n      <li>Lorax (BR);</li>\n      <li>Loraxen (BD);</li>\n      <li>Lorazep (TH);</li>\n      <li>Lorazepam-Efeka (LU);</li>\n      <li>Lorazepam-Eurogenerics (LU);</li>\n      <li>Lorazin (TW);</li>\n      <li>Lorenin (PT);</li>\n      <li>Loridem (BE, LU);</li>\n      <li>Lorivan (IL, MT, TR);</li>\n      <li>Lorsilan (HR);</li>\n      <li>Lozam (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Lozicum (BD, HK);</li>\n      <li>Merlit (AT, RU);</li>\n      <li>Merlopam (ID);</li>\n      <li>Nervistop L (AR);</li>\n      <li>Neuropam (TW);</li>\n      <li>Novhepar (GR);</li>\n      <li>Orfidal (ES);</li>\n      <li>Renaquil (ID);</li>\n      <li>Rilex (HU);</li>\n      <li>Sedatival (AR);</li>\n      <li>Sidenar (AR);</li>\n      <li>Silence (HK, TW);</li>\n      <li>Stapam (TW);</li>\n      <li>Tavor (BG, CZ, DE, GR, IT, TR);</li>\n      <li>Temesta (AT, BE, CH, DK, FI, FR, LU, NL, SE);</li>\n      <li>Titus (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, GR, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);</li>\n      <li>Tranqipam (ZA);</li>\n      <li>Trapax (AR, PY);</li>\n      <li>Trapex (BD, IN);</li>\n      <li>Vigiten (LU);</li>\n      <li>Zora (TH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Abernethy DR, Greenblatt DJ, Ameer B, et al, &ldquo;Probenecid Impairment of Acetaminophen and Lorazepam Clearance: Direct Inhibition of Ether Glucuronide Formation,&rdquo; <i>J Pharmacol Exp Ther</i>, 1985, 234(2):345-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/4020675/pubmed\" target=\"_blank\" id=\"4020675\">4020675</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alldredge BK, Gelb AM, Isaacs SM, et al, &ldquo;A Comparison of Lorazepam, Diazepam, and Placebo for the Treatment of Out-of-Hospital Status Epilepticus,&rdquo; <i>N Engl J Med</i>, 2001, 345(9):631-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/11547716/pubmed\" target=\"_blank\" id=\"11547716\">11547716</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16319571\"></a>Allen MH, Currier GW, Carpenter D, et al, &ldquo;The Expert Consensus Guideline Series. Treatment of Behavioral Emergencies 2005,&rdquo; <i>J Psychiatr Pract</i>, 2005, 11 (Suppl 1):5-108.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/16319571/pubmed\" target=\"_blank\" id=\"16319571\">16319571</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ameer B and Greenblatt DJ, &ldquo;Lorazepam: A Review of Its Clinical Pharmacological Properties and Therapeutic Uses,&rdquo; <i>Drugs</i>, 1981, 21(3):162-200.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/6114848/pubmed\" target=\"_blank\" id=\"6114848\">6114848</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2015;63(11):2227-2246. doi:10.1111/jgs.13702.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/26446832/pubmed\" target=\"_blank\" id=\"26446832\">26446832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson GD, Gidal BE, Kantor ED, et al, &ldquo;Lorazepam-Valproate Interaction: Studies in Normal Subjects and Isolated Perfused Rat Liver,&rdquo; <i>Epilepsia</i>, 1994, 35(1):221-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/8112251/pubmed\" target=\"_blank\" id=\"8112251\">8112251</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Apo-Lorazepam [product monograph]. Toronto, Ontario, Canada: Apotex Inc; August 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 126, 182.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Arroliga AC, Shehab N, McCarthy K, et al, &ldquo;Relationship of Continuous Infusion Lorazepam to Serum Propylene Glycol Concentration in Critically Ill Adults,&rdquo; <i>Crit Care Med</i>, 2004, 32(8):1709-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/15286548/pubmed\" target=\"_blank\" id=\"15286548\">15286548</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ativan (lorazepam) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada Inc; October 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ativan injection (lorazepam) [prescribing information]. Eatontown, NJ: West-Ward; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ativan tablet (lorazepam) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barnes BJ, Gerst C, Smith JR, et al, &ldquo;Osmol Gap as a Surrogate Marker for Serum Propylene Glycol Concentrations in Patients Receiving Lorazepam for Sedation,&rdquo; <i>Pharmacotherapy</i>, 2006, 26(1):23-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/16422667/pubmed\" target=\"_blank\" id=\"16422667\">16422667</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barr J, Fraser GL, Puntillo K, et al, &ldquo;Clinical Practice Guidelines for the Management of Pain, Agitation, and Delirium in Adult Patients in the Intensive Care Unit,&rdquo; <i>Crit Care Med</i>, 2013, 41(1):263-306.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/23269131/pubmed\" target=\"_blank\" id=\"23269131\">23269131</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15916448\"></a>Battaglia J, &quot;Pharmacological Management of Acute Agitation,&quot; <i>Drugs</i>, 2005, 65(9):1207-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/15916448/pubmed\" target=\"_blank\" id=\"15916448\">15916448</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bergman U, Rosa FW, Baum C, et al, &quot;Effects of Exposure to Benzodiazepine During Fetal Life,&quot; <i>Lancet</i>, 1992, 340(8821):694-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/1355799/pubmed\" target=\"_blank\" id=\"1355799\">1355799</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bishop JF, Olver IN, Wolf MM, et al, &ldquo;Lorazepam: A Randomized, Double-Blind, Crossover Study of a New Antiemetic in Patients Receiving Cytotoxic Chemotherapy and Prochlorperazine,&rdquo; <i>J Clin Oncol</i>, 1984, 2(5):691-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/6374058/pubmed\" target=\"_blank\" id=\"6374058\">6374058</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bleck TB, Seizures, Stroke, and Other Neurologic Emergencies. In: Zimmerman JL, Roberts PR, eds. <i>Multidisciplinary Critical Care Review</i>, Des Plains, IL: Society of Critical Care Medicine; 2003:325-34.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22528274\"></a>Brophy GM, Bell R, Claassen J, et al; Neurocritical Care Society Status Epilepticus Guideline Writing Committee. Guidelines for the evaluation and management of status epilepticus. <i>Neurocrit Care</i>. 2012;17(1):3-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/22528274/pubmed\" target=\"_blank\" id=\"22528274\">22528274</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brunton LL, Chabner BA, Knollmann BC, eds. <i>Goodman &amp; Gilman's The Pharmacological Basis of Therapeutics</i>. 12th ed. New York, NY: McGraw-Hill Medical; 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8686484\"></a>Bush G, Fink M, Petrides G, et al, &quot;Catatonia. II. Treatment With Lorazepam and Electroconvulsive Therapy,&quot; <i>Acta Psychiatr Scand</i>, 1996, 93(2):137-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/8686484/pubmed\" target=\"_blank\" id=\"8686484\">8686484</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Buzdar AU, Esparza L, Natale R, et al, &ldquo;Lorazepam-Enhancement of the Antiemetic Efficacy of Dexamethasone and Promethazine. A Placebo-Controlled Study,&rdquo; <i>Am J Clin Oncol</i>, 1994, 17(5):417-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/8092114/pubmed\" target=\"_blank\" id=\"8092114\">8092114</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol&mdash;United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chamberlain JM, Capparelli EV, Brown KM, et al. Pharmacokinetics of intravenous lorazepam in pediatric patients with and without status epilepticus. <i>J Pediatr</i>. 2012;160(4):667-672.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/22050870/pubmed\" target=\"_blank\" id=\"22050870\">22050870</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Clark RF, Sage TA, Tunget C, et al, &ldquo;Delayed Onset Lorazepam Poisoning Successfully Reversed by Flumazenil in a Child: Case Report and Review of the Literature,&rdquo; <i>Pediatr Emerg Care</i>, 1995, 11(1):32-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/7739960/pubmed\" target=\"_blank\" id=\"7739960\">7739960</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Crawford TO, Mitchell WG, and Snodgrass SR, &ldquo;Lorazepam in Childhood Status Epilepticus and Serial Seizures: Effectiveness and Tachyphylaxis,&rdquo; <i>Neurology</i>, 1987, 37(2):190-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/3808299/pubmed\" target=\"_blank\" id=\"3808299\">3808299</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15276655\"></a>De Fruyt J and Demyttenaere K, &quot;Rapid Tranquilization: New Approaches in the Emergency Treatment of Behavioral Disturbances,&quot; <i>Eur Psychiatry</i>, 2004, 19(5):243-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/15276655/pubmed\" target=\"_blank\" id=\"15276655\">15276655</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Department of Veteran Affairs and Department of Defense, &quot;VA/DoD Clinical Practice Guideline for Management of Substance Use Disorders (SUD),&rdquo; 2009. Available at <a href=\"http://www.healthquality.va.gov/Substance_Use_Disorder_SUD.asp\" target=\"_blank\">http://www.healthquality.va.gov/Substance_Use_Disorder_SUD.asp</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Deshmukh A, Wittert W, Schnitzler E, et al, &ldquo;Lorazepam in the Treatment of Refractory Neonatal Seizures: A Pilot Study,&rdquo; <i>Am J Dis Child</i>, 1986, 140(10):1042-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/3752014/pubmed\" target=\"_blank\" id=\"3752014\">3752014</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Divoll M and Greenblatt DJ, &ldquo;Effect of Age and Sex on Lorazepam Protein Binding,&rdquo; <i>J Pharm Pharmacol</i>, 1982, 34(2):122-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/6121874/pubmed\" target=\"_blank\" id=\"6121874\">6121874</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12956617\"></a>Dupuis LL and Nathan PC, &ldquo;Options for the Prevention and Management of Acute Chemotherapy-Induced Nausea and Vomiting in Children,&rdquo; <i>Paediatr Drugs</i>, 2003, 5(9):597-613.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/12956617/pubmed\" target=\"_blank\" id=\"12956617\">12956617</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24753095\"></a>Dupuis LL, Robinson PD, Boodhan S, et al; Pediatric Oncology Group of Ontario. Guideline for the prevention and treatment of anticipatory nausea and vomiting due to chemotherapy in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2014;61(8):1506-1512. doi: 10.1002/pbc.25063.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/24753095/pubmed\" target=\"_blank\" id=\"24753095\">24753095</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21677256\"></a>England ML, Ong&uuml;r D, Konopaske GT, Karmacharya R. Catatonia in psychotic patients: clinical features and treatment response. <i>J Neuropsychiatry Clin Neurosci</i>. 2011;23(2):223-226.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/21677256/pubmed\" target=\"_blank\" id=\"21677256\">21677256</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Federal Drug Administration. General Anesthetic and seation drugs; drug safety communication - FDA approves label changes for use in young children. Food and Drug Administration website. <a href=\"https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm555631.htm?source=govdelivery&amp;utm_medium=email&amp;utm_source=govdelivery\" target=\"_blank\">https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm555631.htm?source=govdelivery&amp;utm_medium=email&amp;utm_source=govdelivery</a>. Accessed July 6, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fraser AD and Bryan W, &ldquo;Evaluation of the Abbott TDx Serum Benzodiazepine Immunoassay for the Analysis of Lorazepam, Adinazolam, and N-Desmethyladinazolam,&rdquo; <i>J Anal Toxicol</i>, 1995, 19(5):281-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/7500613/pubmed\" target=\"_blank\" id=\"7500613\">7500613</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26900382\"></a>Glauser T, Shinnar S, Gloss D, et al. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the Guideline Committee of the American Epilepsy Society. <i>Epilepsy Curr</i>. 2016;16(1):48-61. doi:10.5698/1535-7597-16.1.48.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/26900382/pubmed\" target=\"_blank\" id=\"26900382\">26900382</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Greenblatt DJ, Allen MD, Locniskar A, et al, &ldquo;Lorazepam Kinetics in the Elderly,&rdquo; <i>Clin Pharmacol Ther</i>, 1979, 26(1):103-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/36252/pubmed\" target=\"_blank\" id=\"36252\">36252</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Greenblatt DJ, Shader RI, and Abernethy DR. Drug therapy. Current status of benzodiazepines. <i>N Engl J Med</i>. 1983;309(6):354-358.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/6135156/pubmed\" target=\"_blank\" id=\"6135156\">6135156</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Grillo JA and Barie PS, &quot;Precipitation of Lorazepam During Infusion by Volumetric Pump,&quot; <i>Am J Health Syst Pharm</i>, 1996, 53(15):1850.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/8842318/pubmed\" target=\"_blank\" id=\"8842318\">8842318</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Guterman B, Sebastian P, and Sodha N, &ldquo;Recovery From Alpha Coma After Lorazepam Overdose,&rdquo; <i>Clin Electroencephalogr</i>, 1981, 12(4):205-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/6121636/pubmed\" target=\"_blank\" id=\"6121636\">6121636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18245435\"></a>Hegenbarth MA; American Academy of Pediatrics Committee on Drugs. Preparing for pediatric emergencies: drugs to consider. <i>Pediatrics</i>. 2008;121(2):433-443.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/18245435/pubmed\" target=\"_blank\" id=\"18245435\">18245435</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hayman M, Seidl EC, Ali M, et al, &ldquo;Acute Tubular Necrosis Associated With Propylene Glycol From Concomitant Administration of Intravenous Lorazepam and Trimethoprim-sulfamethoxazole,&rdquo; <i>Pharmacotherapy</i>, 2003, 23(9):1190-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/14524651/pubmed\" target=\"_blank\" id=\"14524651\">14524651</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Henry DW, Burwinkle JW, and Klutman NE, &ldquo;Determination of Sedative and Amnestic Doses of Lorazepam in Children,&rdquo; <i>Clin Pharm</i>, 1991, 10(8):625-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/1934919/pubmed\" target=\"_blank\" id=\"1934919\">1934919</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"28759346\"></a>Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. <i>J Clin Oncol</i>. 2017;35(28):3240-3261. doi: 10.1200/JCO.2017.74.4789.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/28759346/pubmed\" target=\"_blank\" id=\"28759346\">28759346</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Iqbal MM, Sobhan T, Ryals T, et al, &quot;Effects of Commonly Used Benzodiazepines on the Fetus, the Neonate, and the Nursing Infant,&quot; <i>Psychiatr Serv</i>, 2002, 53(1):39-49.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/11773648/pubmed\" target=\"_blank\" id=\"11773648\">11773648</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S, Blajchman A, Stephenson M, et al, &quot;Prospective Follow-Up of Adverse Reactions in Breast-Fed Infants Exposed to Maternal Medication,&quot; <i>Am J Obstet Gynecol</i>, 1993, 168(5):1393-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/8498418/pubmed\" target=\"_blank\" id=\"8498418\">8498418</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Johnson TJ, Voss G. Continuous infusion of undiluted lorazepam injection. <i>Am J Health Syst Pharm</i>. 2002;59(1):78-79.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/11813472/pubmed\" target=\"_blank\" id=\"11813472\">11813472</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kalviainen R, &ldquo;Status Epilepticus Treatment Guidelines,&rdquo; <i>Epilepsia</i>, 2007, 48(Suppl 8):99-102.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/18330014/pubmed\" target=\"_blank\" id=\"18330014\">18330014</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kelly LE, Poon S, Madadi P, Koren G. Neonatal benzodiazepines exposure during breastfeeding. <i>J Pediatr</i>. 2012;161(3):448-451.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/22504099/pubmed\" target=\"_blank\" id=\"22504099\">22504099</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lapierre YD and Labelle A, &ldquo;Manic-Like Reaction Induced by Lorazepam Withdrawal,&rdquo; <i>Can J Psychiatry</i>, 1987, 32(8):697-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/3690487/pubmed\" target=\"_blank\" id=\"3690487\">3690487</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Larsen ER, Damkier P, Pedersen LH, et al. Use of psychotropic drugs during pregnancy and breast-feeding. <i>Acta Psychiatr Scand Suppl</i>. 2015;(445):1-28.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/26344706/pubmed\" target=\"_blank\" id=\"26344706\">26344706</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Laszlo J, Clark RA, Hanson DC, et al, &ldquo;Lorazepam in Cancer Patients Treated With Cisplatin: A Drug Having Antiemetic, Amnesic, and Anxiolytic Effects,&rdquo; <i>J Clin Oncol</i>, 1985, 3(6):864-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/4040158/pubmed\" target=\"_blank\" id=\"4040158\">4040158</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lee DS, Wong HA, and Knoppert DC, &ldquo;Myoclonus Associated With Lorazepam Therapy in Very-Low-Birth-Weight Infants,&rdquo; <i>Biol Neonate</i>, 1994, 66(6):311-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/7727612/pubmed\" target=\"_blank\" id=\"7727612\">7727612</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lee ME, Lugo RA, Rusho WJ, et al, &quot;Chemical Stability of Extemporaneously Prepared Lorazepam Suspension at Two Temperatures,&quot; <i>J Pediatr Pharmacol Ther</i>, 2004, 9(4):254-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/23118704/pubmed\" target=\"_blank\" id=\"23118704\">23118704</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lee SA, Lee JK, Heo K, &ldquo;Coma Probably Induced by Lorazepam-Valproate Interaction,&rdquo; <i>Seizure</i>, 2002, 11(2):124-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/11945099/pubmed\" target=\"_blank\" id=\"11945099\">11945099</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lemmer P, Schneider S, M&uuml;he A, Wennig R. Quantification of lorazepam and lormetazepam in human breast milk using GC-MS in the negative chemical ionization mode. <i>J Anal Toxicol</i>. 2007;31(4):224-226.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/17555647/pubmed\" target=\"_blank\" id=\"17555647\">17555647</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lheureux P and Askenasi R, &ldquo;Specific Treatment of Benzodiazepine Overdose,&rdquo; <i>Hum Toxicol</i>, 1988, 7(2):165-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/3132418/pubmed\" target=\"_blank\" id=\"3132418\">3132418</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lohr L. Chemotherapy-induced nausea and vomiting. <i>Cancer J</i>. 2008;14(2):85-93<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/18391612 /pubmed\" target=\"_blank\" id=\"18391612 \">18391612 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lugo RA, Chester EA, Cash J, et al, &ldquo;A Cost Analysis of Enterally Administered Lorazepam in the Pediatric Intensive Care Unit,&rdquo; <i>Crit Care Med</i>, 1999, 27(2):417-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/10075070/pubmed\" target=\"_blank\" id=\"10075070\">10075070</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Malik IA, Khan WA, Qazilbash M, et al, &ldquo;Clinical Efficacy of Lorazepam in Prophylaxis of Anticipatory, Acute, and Delayed Nausea and Vomiting Induced by High Doses of Cisplatin. A Prospective Randomized Trial,&rdquo; <i>Am J Clin Oncol</i>, 1995, 18(2):170-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/7900711/pubmed\" target=\"_blank\" id=\"7900711\">7900711</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Manno EM, &ldquo;New Management Strategies in the Treatment of Status Epilepticus,&rdquo; <i>Mayo Clin Proc</i>, 2003, 78(4):508-18.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/12683704/pubmed\" target=\"_blank\" id=\"12683704\">12683704</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marshall JD, Farrar HC, and Kearns GL, &ldquo;Diarrhea Associated With Enteral Benzodiazepine Solutions,&rdquo; <i>J Pediatr</i>, 1995, 126(4):657-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/7699551/pubmed\" target=\"_blank\" id=\"7699551\">7699551</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"9214531\"></a>Mayo-Smith MF, &quot;Pharmacological Management of Alcohol Withdrawal. A Meta-analysis and Evidence-Based Practice Guideline. American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal,&quot; <i>JAMA</i>, 1997, 278(2):144-51<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/9214531/pubmed\" target=\"_blank\" id=\"9214531\">9214531</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15249349\"></a>Mayo-Smith MF, Beecher LH, Fischer TL, et al. Management of Alcohol Withdrawal Delirium. An Evidence-Based Practice Guideline [published correction appears in<i> Arch Intern Med</i>. 2004;164(18):2068]. <i>Arch Intern Med</i>. 2004;164(13):1405-1412.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/15249349/pubmed\" target=\"_blank\" id=\"15249349\">15249349</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McDermott CA, Kowalczyk AL, Schnitzler ER, et al, &ldquo;Pharmacokinetics of Lorazepam in Critically Ill Neonates With Seizures,&rdquo; <i>J Pediatr</i>, 1992, 120(3):479-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/1538303/pubmed\" target=\"_blank\" id=\"1538303\">1538303</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nelsen JL, Haas, CE, Habtemariam B, et al, &ldquo;A Prospective Evaluation of Propylene Glycol Clearance and Accumulation During Continuous-Infusion Lorazepam in Critically Ill Patients,&rdquo; <i>J Intens Care Med</i>, 2008, 23(3):184-94.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/18543419/pubmed\" target=\"_blank\" id=\"18543419\">18543419</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pandharipande PP, Pun BT, Herr DL, et al, &ldquo;Effect of Sedation With Dexmedetomidine Vs Lorazepam on Acute Brain Dysfunction in Mechanically Ventilated Patients: The MENDS Randomized Controlled Trial,&rdquo; <i>JAMA</i>, 2007, 298(22):2644-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/1807336/pubmed\" target=\"_blank\" id=\"1807336\">1807336</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19969591\"></a>Rosebush PI and Mazurek MF, &ldquo;Catatonia and Its Treatment,&rdquo; <i>Schizophr Bull</i>, 2010, 36(2):239-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/19969591/pubmed\" target=\"_blank\" id=\"19969591\">19969591</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"2211547\"></a>Rosebush PI, Hildebrand AM, Furlong BG, et al, &ldquo;Catatonic Syndrome in a General Psychiatric Inpatient Population: Frequency, Clinical Presentation, and Response to Lorazepam,&rdquo; <i>J Clin Psychiatry</i>, 1990, 51(9):357-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/2211547/pubmed\" target=\"_blank\" id=\"2211547\">2211547</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Samara EE, Granneman RG, Witt GF, et al, &ldquo;Effect of Valproate on the Pharmacokinetics and Pharmacodynamics of Lorazepam,&rdquo; <i>J Clin Pharmacol</i>, 1997, 37(5):442-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/9156377/pubmed\" target=\"_blank\" id=\"9156377\">9156377</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Scharf MB, Kales A, Bixler EO, &ldquo;Lorazepam &ndash; Efficacy, Side Effects, and Rebound Phenomena,&rdquo; <i>Clin Pharmacol Ther</i>, 1982, 31(2):175-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/6120058/pubmed\" target=\"_blank\" id=\"6120058\">6120058</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"28006997\"></a>Soyka M, Kranzler HR, Hesselbrock V, Kasper S, Mutschler J, M&ouml;ller HJ; WFSBP Task Force on Treatment Guidelines for Substance Use Disorders. Guidelines for biological treatment of substance use and related disorders, part 1: Alcoholism, first revision. <i>World J Biol Psychiatry</i>. 2017;18(2):86-119. doi: 10.1080/15622975.2016.1246752.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/28006997/pubmed\" target=\"_blank\" id=\"28006997\">28006997</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stanford GK and Pine RH, &ldquo;Postburn Delirium Associated With Use of Intravenous Lorazepam,&rdquo; <i>J Burn Care Rehabil</i>, 1988, 9(2):160-1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/3360819/pubmed\" target=\"_blank\" id=\"3360819\">3360819</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stein MB, Goin MK, Pollack MH, et al, &ldquo;Practice Guideline for the Treatment of Patients Disorder, Second Edition,&rdquo; 2009. Available at http://psychiatryonline.org/pdfaccess.ashx?ResourceID=243182&amp;PDFSource=6</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Treatment of Convulsive Status Epilepticus. Recommendations of the Epilepsy Foundation of America's Working Group on Status Epilepticus,&rdquo; <i>JAMA</i>, 1993, 270(7):854-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/8340986/pubmed\" target=\"_blank\" id=\"8340986\">8340986</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Treiman DM, Meyers PD, Walton NY, et al, &ldquo;A Comparison of Four Treatments for Generalized Convulsive Status Epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group,&rdquo; <i>N Engl J Med</i>, 1998, 339(12):792-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/9738086/pubmed\" target=\"_blank\" id=\"9738086\">9738086</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Uchaipichat V, Mackenzie PI, Guo XH, et al, &ldquo;Human UDP-Glucuronosyltransferases: Isoform Selectivity and Kinetics of 4-Methylumbelliferone and 1-Naphthol Glucuronidation, Effects of Organic Solvents, and Inhibition by Diclofenac and Probenecid,&rdquo; <i>Drug Metab Dispos</i>, 2004, 32(4):413-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/15039294/pubmed\" target=\"_blank\" id=\"15039294\">15039294</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vinkers CH, Olivier B. Mechanisms underlying tolerance after long-term benzodiazepine use: a future for subtype-selective gaba(a) receptor modulators? <i>Adv Pharmacol Sci</i>. 2012;2012:1-19.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/22536226/pubmed\" target=\"_blank\" id=\"22536226\">22536226</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vlachos P, Kentarchou P, Poulosa L, et al, &ldquo;Lorazepam Poisoning,&rdquo; <i>Toxicol Lett</i>, 1978, 2:109-10.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    von Moltke LL, Manis M, Harmatz JS, et al, &ldquo;Inhibition of Acetaminophen and Lorazepam Glucuronidation In Vitro by Probenecid,&rdquo; <i>Biopharm Drug Dispos</i>, 1993, 14(2):119-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/8453022/pubmed\" target=\"_blank\" id=\"8453022\">8453022</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"6378615\"></a>Walker JE, Homan RW, and Crawford IL. &ldquo;Lorazepam: A Controlled Trial In Patients With Intractable Partial Complex Seizures,&rdquo; <i>Epilepsia</i>, 1984, 25(4):464-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/6378615/pubmed\" target=\"_blank\" id=\"6378615\">6378615</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wang RIH, Stockdale SL, and Heib E, &ldquo;Hypnotic Efficacy of Lorazepam and Flurazepam,&rdquo; <i>Clin Pharmacol Ther</i>, 1976, 19(2):191-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/4255/pubmed\" target=\"_blank\" id=\"4255\">4255</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Whitelaw AG, Cummings AJ, McFadyen IR. Effect of maternal lorazepam on the neonate. <i>Br Med J (Clin Res Ed)</i>. 1981;282(6270):1106-1108.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/6113019/pubmed\" target=\"_blank\" id=\"6113019\">6113019</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wikner BN, Stiller CO, Bergman U, et al, &quot;Use of Benzodiazepines and Benzodiazepine Receptor Agonists During Pregnancy: Neonatal Outcome and Congenital Malformations,&quot; <i>Pharmacoepidemiol Drug Saf</i>, 2007, 16(11):1203-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/17894421/pubmed\" target=\"_blank\" id=\"17894421\">17894421</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wiley J and Wiley C, &ldquo;Benzodiazepine Ingestions in Children,&rdquo; <i>Clin Toxicol</i>, 1995, 33(5):520.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22461918\"></a>Wilson MP, Pepper D, Currier GW, Holloman GH Jr, Feifel D. The psychopharmacology of agitation: consensus statement of the american association for emergency psychiatry project Beta psychopharmacology workgroup. <i>West J Emerg Med</i>. 2012;13(1):26-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/22461918/pubmed\" target=\"_blank\" id=\"22461918\">22461918</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26444730\"></a>Winkelman JW. Clinical Practice. Insomnia Disorder. <i>N Engl J Med</i>. 2015 Oct 8;373(15):1437-1444.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/26444730/pubmed\" target=\"_blank\" id=\"26444730\">26444730</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the Eleventh WHO Model List of Essential Drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/23215911</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18657015\"></a>Yahwak JA, Riker RR, Fraser GL, Subak-Sharpe S. Determination of a lorazepam dose threshold for using the osmol gap to monitor for propylene glycol toxicity. <i>Pharmacotherapy</i>. 2008;28(8):984-991.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/18657015/pubmed\" target=\"_blank\" id=\"18657015\">18657015</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yaucher NE, Fish JT, Smith HW, et al, &ldquo;Propylene Glycol-Associated Renal Toxicity From Lorazepam Infusion,&rdquo; <i>Pharmacotherapy</i>, 2003, 23(9):1094-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/14524641/pubmed\" target=\"_blank\" id=\"14524641\">14524641</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. Semin Dial. 2007;20(3):217-219.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/17555487/pubmed\" target=\"_blank\" id=\"17555487\">17555487</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20399981\"></a>Zeller SL, Rhoades RW. Systematic reviews of assessment measures and pharmacologic treatments for agitation. <i>Clin Ther</i>. 2010;32(3):403-425.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-drug-information/abstract-text/20399981/pubmed\" target=\"_blank\" id=\"20399981\">20399981</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9573 Version 266.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F49334833\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F189926\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F50781432\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F189973\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F189931\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F189951\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F189932\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F4413000\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F4413001\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F189896\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F189880\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F24129223\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Controlled Substance\" href=\"#F189975\" class=\"outlineLink\">Controlled Substance</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F49468920\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F189901\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F189900\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25472939\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F189983\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F189887\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F189904\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F189884\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299616\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F189889\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F189908\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F189909\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F189893\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F189883\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F189903\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F189907\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F189910\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9573|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=lorazepam-patient-drug-information\" class=\"drug drug_patient\">Lorazepam: Patient drug information</a></li><li><a href=\"topic.htm?path=lorazepam-pediatric-drug-information\" class=\"drug drug_pediatric\">Lorazepam: Pediatric drug information</a></li></ul></div></div>","javascript":null}